Ageing impairs endothelial function, which is considered a hallmark of the development of cardiovascular diseases in elderly. Cilostazol, a phosphodiesterase-3 inhibitor, has antiplatelet, antithrombotic and protective effects on endothelial cells. Here, we hypothesized that cilostazol could improve endothelial function in mesenteric resistance arteries (MRA) from old rats. Using eight-week cilostazol-treated (100 mg/kg/day) or untreated 72-week-old Wistar rats, we evaluate the relaxation to acetylcholine, sodium nitroprusside (SNP), forskolin and isoproterenol and the noradrenaline-induced contraction in MRA. Superoxide anion and nitric oxide (NO) was measured by dihydroethidium-and diaminofluorescein-2-emitted fluorescence, respectively. Normotensive old rats had impaired acetylcholine-induced NO-and EDHF-mediated relaxation and increased noradrenaline vasoconstriction than young rats. This age-associated endothelial dysfunction was restored by cilostazol treatment. Relaxation to SNP, forskolin or isoproterenol remained unmodified by cilostazol. Diaminofluorescein-2-emitted fluorescence was increased while dihydroethidium-emitted was decreased by cilostazol, indicating increased NO and reduced superoxide generation, respectively. Cilostazol improves endothelial function in old MRA without affecting blood pressure. This protective effect of cilostazol could be attributed to reduced oxidative stress, increased NO bioavailability and EDHF-type relaxation. Although these results are preliminary, we believe that should stimulate further interest in cilostazol as an alternative for the treatment of age-related vascular disorders.
Introduction
Cardiovascular diseases (CVD) remain the leading cause of death worldwide, and the ageing process is the main risk factor for developing CVD (Lakatta and Levy, 2010) . Ageing, independently of other risk factors, courses with complex structural and functional vascular changes, contributing to higher incidence and prevalence rates of CVD in the elderly population (Barodka et al., 2011) . One of the most clinically important of these vascular changes is the development of endothelial dysfunction, which is one of the main mechanisms by which ageing increases the risk of CVD. In aged vessels, this process is mainly characterized by a reduction of the NO bioavailability caused by impaired NO synthesis and/or by increased NO scavenging due to oxidative stress, impaired EDHF-type relaxation, increased vasoconstrictor factors production and/or activity and inflammation (Rodriguez-Mañas et al., 2009; El Assar et al., 2012) . Age-related endothelial dysfunction is a progressive phenomenon and the major antecedent to atherosclerosis and thrombosis, a predictor of clinic CVD (Lakatta and Levy, 2010) . Therefore, strategies to minimize the effect of ageing on endothelial function could be an important therapeutic target in cases involving age-related vasculopathy (Mensah et al., 2007; Toda, 2012) .
In recent years, phosphodiesterase (PDE) inhibitors are being widely used for producing broad vasodilatory effects. Cilostazol, a selective PDE3 inhibitor, was originally described as an antiplatelet agent to treat intermittent claudication and ischemic symptoms related to chronic peripheral arterial obstruction and to prevent secondary cerebral ischemia (Dawson et al., 1998; Gotoh et al., 2000; Kambayashi et al., 2003) . However, it has been largely reported that cilostazol has other pharmacological actions, including vasodilator (Li et al., 2015) and anti-dyslipidemic (Ikewaki et al., 2002) actions. Cilostazol also inhibits superoxide anion generation (Sakurada et al., 2010) , proliferation of vascular smooth muscle cells and restenosis in animals and humans (Lida et al., 2008) .
In the last decade, preclinical studies demonstrated that cilostazol protects endothelial cells from glucose-induced apoptosis, serum deprivation and lipopolysaccharide exposition (Kim et al., 2002) . Moreover, this drug attenuates the expression of cell adhesion molecules and monocyte chemoattractant protein-1, thus preventing monocyte adhesion to endothelial cells (Otsuki et al., 2001) . Lee et al. (2005) have shown that cilostazol has anti-atherosclerotic effects due its reducing actions of the inflammatory and oxidative processes. Moreover, some studies demonstrated that cilostazol protects endothelial cells and nervous tissue in focal ischemia models, independently of its antiplatelet activity (Oyama et al., 2011) . Based on these effects, cilostazol has been quite studied in several disorders that course with endothelial dysfunction (Matsumoto et al., 2005 (Matsumoto et al., , 2008 Suzuki et al., 2008; Sakurada et al., 2010; Takagi et al., 2014) . Although there are considerable evidences showing that cilostazol has beneficial effects on endothelial function in several pathophysiological conditions, to our knowledge, no study has yet investigated the effects of chronic cilostazol treatment on age-related endothelial dysfunction. Thus, our study was designed to evaluate the effect of chronic treatment with cilostazol on vascular reactivity (contractile and relaxing mechanisms), using mesenteric resistance arteries isolated from old rats.
Material and methods

Animals
All procedures used in this study conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication, 2011) and were approved by the Committee for Ethics in Animal Experimentation of the Universidade Federal de Pernambuco (UFPE) (Protocol number: 23076.057069/2014-31) . 12-and 72-week-old male Wistar rats were obtained from colonies maintained at the Animal Quarters of the Departamento de Fisiologia e Farmacologia of the UFPE. Rats were housed in individually ventilated cages (425 mm × 266 mm × 185 mm; Tecniplast, Buguggiate, Italy) with three animals in each cage. The room where they were kept had a 12-12 h light-dark cycle, and the temperature was regulated within the range of 22-24°C. Rats had free access to tap water and standard rat chow ad libitum. 72-weeks-old rats were chronically given cilostazol (100 mg/kg/day, administered by gavage) for 8 weeks starting at 63-64 weeks old. Thus, we studied three groups: young (12-week-old rats), old (72-week-old rats) and cilostazol (CLZ)-treated old rats (old-CLZ). After the treatment period, both groups were subjected to experiments of blood pressure measurements and vascular reactivity studies.
Arterial blood pressure measurement in conscious rats
For arterial pressure measurements, rats were anesthetized with ketamine and xylazine mixture (80 mg/kg and 5 mg/kg, respectively, i.p.). A polyethylene catheter (PE-50, Clay Adams, Parsippany, NJ, USA) was inserted into the right carotid artery for direct arterial pressure measurement. The distal end of the catheter was tunneled subcutaneously, exteriorized in the mid scapular region and sutured to the skin, which allows the rat freedom of movement. At the end of the surgery, intramuscular injection of the analgesic and anti-inflammatory ketoprofen (5 mg/kg, i.m., Venco Laboratory, Londrina, Brazil) was performed. Animals were allowed free access to food and water. After 24 h, arterial blood pressure was measured in conscious animals by a pressure transducer (MLT0380; ADInstruments Pty Ltd, Castle Hill, New South Wales, Australia) connected to an amplifier (Bridge Amp, ML224; ADInstruments) and an acquisition system (PowerLab 4/30, ML866; ADInstruments), and the signals were digitized with appropriate software (Chart Pro; ADInstruments). The cardiovascular parameters were recorded for 60 min, but only the last 30 min were considered for data analysis.
Vascular reactivity study
Rats were anaesthetized with ketamine and xylazine mixture (80 mg/kg and 5 mg/kg, respectively, i.p.) and killed by exsanguination. The mesenteric vascular bed was carefully removed and placed in cold (4°C) oxygenated Krebs-Henseleit bicarbonate buffer (KHB). The buffer consisted of (in mM): NaCl 118, KCl 4.7, NaHCO 3 25; CaCl 2 ·2H 2 O 2.5, glucose 11, KH 2 PO 4 1.2, 1.2 and EDTA MgSO 4 ·7H 2 O 0.01). The third-order branch of the mesenteric arcade was dissected and cut into segments of approximately 2 mm in length. Arterial segments were mounted between two tungsten wires (40 µm diameter) in a small vessel chamber myograph (Danish Myo Technology A/S, Aarhus, Denmark) to measure isometric tension according to the method described by Mulvany and Halpern (1977) . After a 15-min equilibration period in oxygenated KHB at 37°C and pH 7.4, arterial segments were stretched to their optimal lumen diameter for active tension development. Optimal lumen diameter was determined based on the internal circumference/wall tension ratio of the segments by setting the internal circumference, L 0 , to 90% of what the vessels would have if they were exposed to a passive tension equivalent to that produced by a transmural pressure of 100 mmHg. Optimal lumen diameter was determined using specific software for normalization of resistance arteries (DMT Normalization Module; ADInstruments Pty Ltd, Castle Hill, Australia). Segments were washed with KHB and left to equilibrate for 45 min.
Experimental protocols
After equilibration period, vessel contractility was tested by an initial exposure to a high-K + (120 mmol/l) solution. After washout period of 30 min, MRA were contracted with noradrenaline (10 μmol/l, Sigma, St. Louis, MO, USA) and then concentration-response curves to acetylcholine (1 nmol/l to 10 μmol/l, Sigma, St. Louis, MO, USA) were performed. After a washout period of 60 min, concentration-response curves to noradrenaline (0.1 nmol/l to 10 μmol/l) were constructed in endothelium-intact or -denuded segments. In another set of experiments, the relaxation to sodium nitroprusside (1 nmol/l to 10 μmol/l, (Sigma, St. Louis, MO, USA), isoproterenol (1 nmol/l to 10 μmol/l, (Sigma, St. Louis, MO, USA) or forskolin (1 nmol/l to 10 μmol/l, (Sigma, St. Louis, MO, USA) was analysed in endothelium-denuded MRA. The endothelium was removed by gently rubbing the intimal surface with a human hair. The effectiveness of endothelium removal was confirmed by the inability of acetylcholine (1 µmol/l) to relax noradrenaline-contracted arteries.
To investigate the influence of the endothelium-derived factors on acetylcholine and noradrenaline responses in intact MRA, we evaluated acetylcholine-induced relaxation and noradrenaline-induced contraction in the absence or presence of various inhibitors, as follows: 1) the soluble guanylyl cyclase inhibitor 1H-1,2,4-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 0.1 μmol/l, Tocris ® , USA) or the nonselective nitric oxide synthase inhibitor N-nitro-L-arginine methyl ester (L-NAME, 100 μmol/l, Sigma, St. Louis, MO, USA); 2) the COX inhibitor indomethacin (10 μmol/l, Sigma, St. Louis, MO, USA); 3) indomethacin plus L-NAME (100 μmol/l, Sigma, St. Louis, MO, USA) and 4) the intermediate-conductance K Ca channel blocker TRAM-34 (10 μmol/l, Sigma, St. Louis, MO, USA) plus the small-conductance K Ca channel blocker apamin (0.1 μmol/l, Sigma, St. Louis, MO, USA). All drugs were added 30 min before generating the concentration-response curve.
Nitric oxide and superoxide anions production
Frozen arterial transverse sections (10 µm) were incubated (30 min) in buffer (37°C) containing 4,5-diaminofluorescein diacetate (DAF-2 DA, 10 μmol/l, Sigma, St. Louis, MO, USA) or with dihydroethidium (DHE, 5 μmol/l, Sigma, St. Louis, MO, USA) for NO and superoxide anions measurements, respectively. Digital images were collected on a microscope (Eclipse 80i, Nikon, Japan) equipped with a rhodamine/ fluorescein filter and camera (DS-U3, Nikon, Japan) using a 20× objective and the same imaging settings in each case. NO availability was evaluated by DAF-2 DA mean optical density of the fluorescence in the endothelium and superoxide anions generation was expressed as the delta of basal integrative density minus in the presence of the superoxide dismutase (SOD) mimetic manganese (III) tetrakis (1-methyl-4-pyridyl) porphyrin (MnTMPyP, 1 μmol/l, Calbiochem). The images were analysed using ImageJ software (NIH, Bethesda, MD, USA) by measurement of the mean optical density of the fluorescence observed in the vessel in relationship to background staining. Six different areas of each section were analysed for the presence of NO or reactive oxygen species by examination of the regions marked with green or red fluorescence, respectively.
Western blotting
Mesenteric resistance arteries (MRA) from young rats and cilostazoltreated and untreated old rats were homogenized; proteins were electrophoretically separated (30 μg per lane) and transferred to polyvinyl difluoride membranes (GE Healthcare do Brasil Ltda, São Paulo, SP, Brazil). Membranes were incubated with antibodies against eNOS (1:500 dilution, BD Biosciences), anti-phospho (Ser 1177 )-eNOS (1:500;
Abcam), anti-Akt (1:500; Santa Cruz Biotechnology), anti-phospho (Ser 473 )-Akt (1:500; Santa Cruz Biotechnology) and individual horseradish peroxidase-conjugated secondary antibodies (GE Healthcare do Brasil Ltda) in blocking buffer. Anti-β-actin (1:500, Santa Cruz Biotechnology) was used to normalize the expression of the evaluated proteins in each sample. Immunoreactive proteins were detected by chemiluminescence with ECL Plus (GE Healthcare do Brasil Ltda). The chemiluminescent signals were captured using ChemiDoc XRS imaging system (Bio-Rad Laboratories, Hercules, CA, USA) and was quantified with Image Lab SoftwareTM version 5.2 (Bio-Rad Laboratories, Hercules, CA, USA).
Statistical analysis
The relaxation responses were expressed as a percentage of the contraction induced by noradrenaline. Contractile responses were expressed as a percentage of the response to KCl. For each Fig. 1 . Endothelium-dependent relaxation to acetylcholine (A) and concentration-dependent vasoconstriction to noradrenaline (B) in mesenteric resistance arteries (MRA) from 12-(young) and 72 (old)-week-old rats. (C and D) Effect of preincubation with L-NAME (C) or apamin plus TRAM-34 (D) on the concentration-dependent relaxation to acetylcholine in MRA from young and old rats. Insert graph shows differences in area under the concentration-response curve (dAUC) to acetylcholine in segments in the absence and in the presence of L-NAME or apamin plus TRAM-34. Results are expressed as mean ± S.E.M. The numbers in parenthesis indicate the number of animals in each group. t-test: *P < 0.05 vs. young rats.
concentration-response curve, the maximal effect (E max ) and the -logarithm of the concentration of agonist that produced half of E max (pD 2 ) were calculated using non-linear regression analysis (GraphPad Prism Software, San Diego, CA, USA). To compare the magnitude of effect of L-NAME or apamin plus TRAM-34 on the vascular responses to acetylcholine and noradrenaline, some results were expressed as differences in the area under the concentration-response curves (dAUC) in control (in absence of L-NAME or apamin plus TRAM-34) and experimental situations (in presence of L-NAME or apamin plus TRAM-34). AUC was calculated from the individual concentration-response curve plot by using GraphPad Prism software and the differences were expressed as a percentage of AUC of the corresponding control situation.
All results were expressed as mean ± standard error of the mean (S.E.M.) of the number of rats used in each experiment. Results were analysed using Student's t-test, one way or "two-way" ANOVA. When ANOVA showed a significant treatment effect, Bonferroni's post hoc test was used to compare individual means (GraphPad Prism Software). Differences were considered statistically significant at P < 0.05.
Results
Blood pressure
There were no differences in systolic (SBP) and diastolic (DBP) blood pressures and heart rate in old rats compared with young ones (SBP: young rats, 124 ± 4.51 vs. old rats, 127 ± 1.62 mmHg, P > 0.05; DBP: young, 82.4 ± 1.36 vs. old rats, 80.5 ± 1.39 mmHg, P > 0.05). These parameters remained unmodified after cilostazol treatment in old rats (SBP: 138 ± 2.40 mmHg; DBP: 80.3 ± 3.31 mmHg). Heart rate was similar in all groups (data not shown).
Endothelium-dependent and independent relaxation and contraction
KCl evoked similar contractions in MRA from young and old rats (young rats: 3.27 ± 0.08 vs. old rats: 3.21 ± 0.14 mN mm −1 , P > 0.05). The endothelium-dependent relaxation to acetylcholine was markedly decreased in old rats compared with young rats (Fig. 1A) . Endothelium-intact MRA from old rats showed an increase of contractile response to noradrenaline compared with the young group (Fig. 1B) . In endothelium-denuded MRA, the response to noradrenaline was similar in both young and old rats (E max : young rats, 110 ± 9.48% vs. old rats, 113 ± 7.52%, P > 0.05; pD 2 : young rats, 6.04 ± 0.03 vs. old rats, 6.09 ± 0.08, P > 0.05). Preincubation with L-NAME eliminated the relaxant response to acetylcholine in MRA from old rats (Fig. 1D ), but only attenuated this response in arteries from young rats (Fig. 1C) . Apamin plus TRAM-34 reduced the response to acetylcholine only in old MRA (Fig. 1D) . As L-NAME abolished the acetylcholine relaxation in old MRA, the addition of apamin plus TRAM-34 had no effect (data not shown). In young MRA the addition of apamin plus TRAM-34 together L-NAME eliminated the vasodilation to acetylcholine (data not shown). The reduction of acetylcholine relaxation by L-NAME or apamin plus TRAM-34 was smaller in arteries from old rats than in arteries from the young group, as shown by the comparison of dAUC values (Fig. 1) . Endothelium-independent vasodilation to the NO donor sodium nitroprusside was not different among the groups (E max : young rats, 73.7 ± 4.55 vs. old rats, 86.0 ± 11.71%, P > 0.05; pD 2 : young rats, 6.63 ± 0.15 vs. old rats, 6.39 ± 0.31, P > 0.05).
In MRA from old rats, chronic cilostazol administration produced a marked increase in endothelium-dependent relaxation evoked by acetylcholine ( Fig. 2A) , while it did not modify the relaxation promoted by the NO donor sodium nitroprusside (Fig. 2B) . KCl induced similar contractions in MRA from cilostazol-treated and untreated rats (untreated rats: 3.24 ± 0.09 vs. cilostazol-treated rats: 3.28 ± 0.08 mN mm −1 , P > 0.05). Cilostazol treatment decreased the noradrenaline-induced contraction in endothelium-intact MRA of old rats (Fig. 2C) . However, in endothelium-denuded MRA, contraction to noradrenaline was comparable in cilostazol-treated and untreated rats (E max : untreated rats, 113 ± 7.52% vs. cilostazol-treated rats, 114 ± 11.7%, P > 0.05; pD 2 : untreated rats, 6.09 ± 0.08 vs. cilostazoltreated rats, 6.08 ± 0.05, P > 0.05).
To identify which endothelium-derived factors might be improved in MRA from cilostazol-treated old rats, acetylcholine curves were generated in the presence of various inhibitors. To analyse the role of NO in acetylcholine responses, experiments were performed in the absence or in the presence of the NO synthase inhibitor L-NAME or the guanylate cyclase inhibitor ODQ. In both groups, acetylcholine-induced relaxation was similarly decreased by L-NAME or ODQ (Fig. 3) ; however, this effect was greater in MRA from cilostazol-treated rats (see the inset dAUC graph in Fig. 3) . Contributions of EDHF to acetylcholineinduced relaxation were assessed following incubation of MRA with apamin plus TRAM-34 and by the measurement of the vasodilation resistant to L-NAME plus indomethacin (EDHF-type relaxation). As shown in Fig. 4A , the combined application of apamin plus TRAM-34 had no significant effect on the response to acetylcholine in MRA from untreated old rats. On the other hand, in MRA from cilostazol-treated group, the relaxation to acetylcholine was blunted in presence of apamin plus TRAM-34 (Fig. 4B) . In presence of L-NAME plus indomethacin, a condition that eliminates relaxation to NO and prostacyclin, the response to acetylcholine was greater in MRA from cilostazol-treated than in untreated rats (Fig. 4C) . Altogether, these results indicate that cilostazol treatment improved endothelial function of old MRA by increase NO-and EDHF-mediated relaxation.
To assess the contribution of NO and EDHF to the noradrenaline responses, experiments were performed in the absence or in the presence of L-NAME or apamin plus TRAM-34, respectively. Under these experimental conditions, the noradrenaline-induced contraction was potentiated only in MRA from cilostazol-treated rats (Fig. 5 , see the inset dAUC graph in Fig. 5 ). Indomethacin alone did not affect acetylcholine or noradrenaline responses in MRA from cilostazol-treated or untreated old rats (data not shown).
In another set of experiments, we evaluated the relaxing responses to the β-adrenergic agonist isoproterenol and to the adenylate cyclase activator forskolin. Both drugs produced similar responses in endothelium-denuded MRA from cilostazol-treated and untreated old rats (Fig. 6 ).
NO and superoxide anions (O 2 -) measurements and eNOS/Akt expression in MRA
As seen in Figs. 7A and 7B, the intensity of fluorescence emitted by DAF-2 DA was decreased in old MRA compared with young MRA, indicating a decrease in NO bioavailability. In MRA from old rats, cilostazol significantly increased the fluorescence emitted by DAF-2 DA, which is consistent with increased NO bioavailability in this group. Reactivity oxygen species generation was detected based on DHEemitted fluorescence. This fluorescence was fully inhibited by the superoxide dismutase mimetic MnTMPyP (data not shown), suggesting superoxide anion (O 2 -) as the main reactivity oxygen specie generated in rat MRA. As seen in Fig. 8 , the intensity of DHE-emitted fluorescence was increased in old MRA compared with young MRA. This fluorescent signal was decreased in arteries from cilostazol-treated-group, indicating decreased O 2 -generation.
Discussion
Endothelial dysfunction is the major antecedent to atherothrombotic damage, which is considered an important event to development of several vasculopathies in the elderly population (Brandes et al., 2005; Mensah et al., 2007) . The proposed mechanisms of agerelated endothelial dysfunction include: 1) decreased NO bioavailability; 2) impaired EDHF-type relaxation; 3) enhancement of oxidative stress; 4) increased vasoconstrictor factors production and/or activity; and 5) inflammation (El Assar et al., 2012; Toda et al., 2012) . The results presented here confirm the endothelial dysfunction with ageing in rats, as evidenced by the substantial decrease in endothelium-dependent relaxation to acetylcholine with a relatively more moderate, albeit significant, increase in reactivity to noradrenaline in MRA from old rats compared with young ones. Our results also reveal that the PDE3 inhibitor cilostazol exerts positive effects on endothelial function of old rats, as demonstrated by the increase of vasodilation to acetylcholine and the decrease of noradrenaline vasoconstriction following cilostazol treatment. The effect of chronic cilostazol in old MRA was limited to the endothelium-mediated responses, since the contraction to noradrenaline and vasodilation to sodium nitroprusside, isoproterenol or forskolin remain unaltered in endothelium-denuded MRA from cilostazol-treated rats. Moreover, K + -induced vasoconstriction was similar in MRA from cilostazol-treated and untreated rats, suggesting that cilostazol does not modify vascular contractile capacity. A possible interpretation of these results is that cilostazol improve acetylcholine and noradrenaline responses, at least in part, by an increase in endothelium-dependent relaxing factors. Further, these findings also indicate that in old MRA, cilostazol exerts a selective enhancing effect on endothelial function, rather than by causing an alteration in vascular smooth muscle reactivity.
The relaxation evoked by acetylcholine is mediated, depending on the vascular bed, by the release of endothelium-dependent relaxing factors such as NO, prostacyclin and EDHF. In rat MRA this relaxation is mainly mediated by the release of NO and EDHF (Lagaud et al., 1999) , but not by COX-derived products (Xavier et al., 2008; Ramos-Alves et al., 2012) . In the present study, COX inhibition (indomethacin) did not affect the response to either acetylcholine or noradrenaline in MRA from cilostazol-treated and untreated rats, confirming the non-participation of COX-derived products in these groups. Studies in vitro have reported that cilostazol increases NO production (Hashimoto et al., 2006) . Indeed, a potentially important finding made in this study was that an improvement in NO release/bioavailability is present in MRA of old rats after cilostazol treatment. This conclusion is supported by evidences showing that under the treatment used to inhibit NO-mediated relaxation (L-NAME or ODQ), the magnitude of changes in acetylcholine and noradrenaline responses (as evidenced by dAUC to acetylcholine and noradrenaline in the absence vs. presence of L-NAME or ODQ) was smaller in old MRA compared to the young ones, which were significantly improved by cilostazol treatment (see inset dAUC graphs in Figs. 3 and 4) . These functional observations are supported by our direct assessments of NO bioavailability using DAF-2 DA-emitted fluorescence. The results obtained revealed that cilostazol treatment increased NO bioavailability in old MRA, which was lower than in young rats. This is probably accomplished by the increase in eNOS phosphorylation induced by cilostazol in old MRA. Thus, phosphorylation at Ser 1177 confers increased activity on eNOS, leading to augmented NO synthesis and enhanced vasodilatation in old MRA. It has been previously reported that activation of PI3K/Akt, via a PKA-independent pathway, is one of the mechanism leading to increased eNOS phosphorylation by cilostazol in human endothelial cells (Hashimoto et al., 2006; Ota et al., 2008) . In line with these results, our experiments showed that chronic exposure to cilostazol increased both total and phosphorylated Akt in MRA from old rats. Taken all together, these findings strongly suggest that the increased NO release induced by cilostazol in old MRA may involve increased PI3K/Akt pathway, promoting increased phosphorylation and thereby activation of eNOS. Additionally, as cilostazol is a PDE3 inhibitor, elevation of cAMP may be implicated. Indeed, it has been reported in endothelial cells in culture that cilostazol increases eNOS activity and NO production through cAMP/PKA-dependent phosphorylation (Hashimoto et al., 2006) . However, to elucidate whether in old MRA cilostazol induces eNOS activation through a cAMP/PKA-dependent mechanism, further investigation is required. It is also assumable that cilostazol suppress O 2 -generation, preventing NO scavenging by oxidative stress Sakurada et al., 2010) . To test this possibility, we measured in situ DHE-emitted fluorescence in absence and in presence of the SOD mimetic MnTMPyP, as an indicator of O 2 -generation. Cilostazol treatment reduced the O 2 -generation in old MRA, which was higher than in young MRA. As oxidative stress has a pivotal role in the development of ageing-induced vascular injury (El Assar et al., 2012) , it is strongly suggested that the capacity of cilostazol to reduced O 2 -generation is one of responsible mechanisms for its protective effects in the age-induced endothelial generation in old MRA is unknown. However, it may involve suppression of NADPH oxidase, as previously reported (Shin et al., 2004) . EDHF plays, in addition to NO, an important vasodilator role in resistance vessels; its effect is endothelium-dependent, insensitive to the combination of NO synthase and COX inhibitors, and induces hyperpolarization of vascular smooth muscle cells (Triggle et al., 2012) . To determine if the effects of cilostazol on the responses of acetylcholine and noradrenaline are due to an increase in EDHF participation, MRA from cilostazol-treated and untreated rats were incubated with apamin plus TRAM-34 (Xavier et al., 2014) . Unlike their effects in young rats, these K + -channels blockers failed to induce changes on the acetylcholine-induced relaxation and noradrenaline-induced contraction in old MRA, indicating that EDHF-mediated responses are essentially absent in this group (Long et al., 2005) . However, in MRA from cilostazol-treated old rats, apamin plus TRAM-34 decreased relaxation to acetylcholine and increased contracting response to noradrenaline, indicating an improvement of the EDHF-type response by cilostazol treatment. This conclusion is reinforced by the fact that the acetylcholine-induced EDHF-type relaxation observed in the presence of L-NAME plus indomethacin was greater in MRA of cilostazol-treated group. The mechanisms underlying the improvement we observed in EDHF-type relaxation following chronic cilostazol treatment is unknown. However, a modulation of the cAMP-signalling pathway may be involved. This speculation is supported by several lines of evidence showing that: 1) cAMP facilitates EDHF-type relaxation in conduit arteries (Griffith et al., 2002) ; 2) cilostazol improves the EDHF response through increases in cAMP/PKA-signalling in the streptozotocin-induced type 1 diabetic mesenteric artery (Matsumoto et al., 2005 (Matsumoto et al., , 2008 ; and 3) the acetylcholine-induced EDHF-type relaxation was significantly reduced by a protein kinase A inhibitor in the control LongEvans Tokushima Otsuka rats (Matsumoto et al., 2006) . Another possibility regarding the mechanism underlying the improvement of EDHFtype relaxation following chronic treatment with cilostazol is that there was reduction in oxidative stress. Although the role of reactive oxygen species in EDHF-type relaxation remains poorly characterized, evidences suggest that radical scavengers improve the EDHF-mediated responses in several disease models when these responses are impaired Fig. 3 . Effect of preincubation with L-NAME (A, B) or ODQ (C, D) on the concentration-dependent relaxation to acetylcholine in mesenteric resistance arteries (MRA) from cilostazol (CLZ)-treated and untreated old rats. Insert graph shows differences in area under the concentration-response curve (dAUC) to acetylcholine in segments in the absence and in the presence of L-NAME or ODQ. Results are expressed as mean ± S.E.M. The numbers in parenthesis indicate the number of animals in each group. t-test: *P < 0.05 vs. young rats. (Ozkan and Uma, 2005; Félétou and Vanhoutte, 2009) .
High intracellular levels of cAMP produce relaxation of vascular smooth muscle mainly by reducing Ca 2+ intracellular concentrations (Lincoln et al., 1990 ). In the current study, the relative contribution of the smooth muscle cAMP pathway to cilostazol actions was analysed by the relaxing effect produced by isoproterenol or forskolin in endothelium-denuded MRA. Stimulation of β-adrenoceptors by isoproterenol and direct activation of adenylate cyclase by forskolin relax vascular smooth muscle cells through cAMP-dependent protein kinase pathway. Results obtained here revealed that cilostazol treatment did not affect the relaxation induced by isoproterenol or forskolin in old MRA. This result was surprising, since by its capacity to inhibit PDE3 and increase cAMP levels, we expected that cilostazol treatment would potentiate the relaxation induced by isoproterenol and/or forskolin. Even so, we cannot rule out the possibility of chronic cilostazol treatment to increase cAMP levels in smooth muscle cells from old MRA.
However, if this cilostazol effect exists, it does not reflect changes in cAMP/PKA-dependent relaxation. Thus, given these functional results we postulate that cilostazol in MRA improves age-related vascular dysfunction preferentially by acting on endothelial cells. A limitation of our findings, however, is that we cannot measure cAMP levels in rat MRA. This was due to the insufficient sample size available to , p-eNOS (E), Akt (F) and p-Akt (G) expressions in MRA from young (n = 4) and cilostazol (CLZ)-treated (n = 6) and untreated (n = 6) old rats. Data (means ± S.E.M.) are expressed as a percentage of elevation over the young value (% C), set to 100% after normalization to β-actin by densitometry. Oneway ANOVA: *P < 0.05 vs. young rats, +P < 0.05 vs. old rats.
adequately estimate cAMP levels. Therefore, it remains unclear whether the effects of chronic cilostazol on NO and EDHF responses involve cAMP-dependent pathways. Further investigation is required on this point. Our results, in concert with previous reports show that cilostazol, in addition to its well-known antiplatelet action, has protective effect against endothelial dysfunction in old rat arteries. Because endothelial dysfunction is considered an early and major promoter for atherosclerosis and thrombosis (Jayakody et al., 1988) , it is expected that improvement of endothelial function is a potentially useful tool to reduce vasculopathies, independent from the benefits of correcting other cardiovascular risk factors. Thus, the protective vascular effects of cilostazol on age-related endothelial dysfunction, as shown in the present study, strongly support a potential therapeutic use of cilostazol for the treatment of arterial ageing.
Conclusions
In conclusion, this study showed for the first time that cilostazol improves endothelial function in old MRA without affecting arterial blood pressure. This protective effect of cilostazol could be attributed to some actions on arterial wall, including reduction in oxidative stress, increase in NO bioavailability and in EDHF-type relaxation. Although these results are preliminary, we believe that should stimulate further interest in cilostazol as an alternative for the prevention/treatment of age-related vascular disorders.
